CO-CSG
11.6.2019 14:02:05 CEST | Business Wire | Press release
As new digital services are deployed to help communications service providers (CSPs) drive innovation, 5G core networks are becoming a necessity to enable true service differentiation. This need is quickly becoming realized, with two-thirds of organizations1 planning to deploy 5G by the end of next year. Not only will CSPs be expected to deliver a fully functional 5G network to meet end-user demand, but success will lie in the ability to provide innovative digital services and to fully monetize their 5G infrastructure investment.
Today, CSG announced the availability of its new 5G Dynamic Charging Function, designed to help CSPs optimize their strategy to not only deliver the value of 5G networks to customers, but also to optimize for sustainable growth in the digital economy. This new capability fulfils the roles of both the 5G Charging Function (CHF) and the Charging Gateway Function (CGF), providing offline and online mediation functionality in a single platform, while managing the complexity of all interfaces between the network and the BSS functions.
“The revenue potential resulting from the deployment of 5G networks should not be underestimated,” said Chad Dunavant, global head of product management, CSG. “But the next generation of business, from 5G to the Internet of Things, requires fundamentally new businesses models. The CSG 5G Dynamic Charging Function gives CSPs the foundation they need to capitalize and monetize on complete industry transformation.”
The CSG 5G Dynamic Charging solution enables operators to:
- Drive service differentiation : Facilitate the monetization of network slicing, enabling charging of tenants and differentiated services by charging in-slice and across slices.
- Minimize risk and disruption to existing systems : Provides a cost effective and efficient way for service providers to seize the 5G opportunity.
- Elastically scale : Automatically scale up to process large charging volumes and down when traffic subsides to optimize infrastructure costs.
- Deliver unparalleled capacity : Process millions of transactions a second with low cost infrastructure to deploy.
- Automate operations : With intelligent tools for diagnostics and troubleshooting.
- Support critical services : Single-digit latencies for real-time online charging transactions.
- Be vendor independent : Support network functions and OSS/BSS systems from any vendor. Eliminates network equipment provider siloes.
- Preserve existing investments : Seamlessly manage the integration of service-based interfaces to existing online charging system interfaces for faster time to market.
With hundreds of global installations, CSG has one of the most trusted mediation and transaction management solutions in the world. CSG supports mediation across any domain, across all mediation functions, for all deployment approaches. The solution captures and processes customer usage events of all kinds from any service delivery network for industry leaders in digital communications and media, financial services, logistics and government.
For more information on how to effectively monetize 5G, download the latest CSG whitepaper here .
About CSG
CSG (NASDAQ: CSGS) is a provider of software and services that help companies around the world monetize and digitally enable the customer experience. For more than 35 years, CSG has simplified the complexity of business, providing revenue management and digital monetization, payments, and customer engagement solutions to help our customers tackle any business challenge and thrive in an ever-changing marketplace.
Operating across more than 120 countries worldwide, CSG manages billions of critical customer interactions annually. CSG is the trusted partner driving digital innovation for hundreds of leading global brands, including Arrow Electronics, AT&T, Charter Communications, Comcast, DISH, Eastlink, Formula One, iflix, MTN and Telstra.
To learn more, visit our website at csgi.com and connect with us on LinkedIn , Twitter and Facebook .
1 Gartner 5G Adoption Survey, December 2018
View source version on businesswire.com: https://www.businesswire.com/news/home/20190611005208/en/
Contact:
Brad Jones Public Relations CSG +1 (303) 200-3001 brad.jones@csgi.com Liz Bauer Investor Relations CSG +1 (303) 804-4065 liz.bauer@csgi.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom